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Revascularization
for Silent Ischemia?
Another Piece of the Puzzle*
David J. Maron, MD,† Judith S. Hochman, MD‡
Nashville, Tennessee; and New York, New York
There are 2 reasons to perform coronary revascularization:
1) improve survival; and 2) improve symptoms. By defini-
tion, revascularization cannot improve the symptoms of
patients with asymptomatic (“silent”) ischemia, leaving im-
provement in survival as the only justifiable reason to
perform revascularization in an asymptomatic person.
See page 1616
Several studies have suggested that silent ischemia wors-
ens prognosis in patients with stable ischemic heart disease
(SIHD) (1–3). Evidence from 2 small, randomized con-
trolled trials—1 in SIHD (ACIP [Asymptomatic Cardiac
Ischemia Pilot study] and 1 in post-myocardial infarction
patients (SWISSI II [Swiss Interventional Study on Silent
Ischemia Type II])—suggests that revascularization im-
proves survival in patients with silent ischemia (4,5). These
studies were limited by their small size (ACIP was a pilot
study) and conduct before contemporary guideline-directed
medical therapy (MT). There was a small subset of patients
with silent ischemia enrolled in the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation) trial (6). Consistent with the overall trial results,
there was no significant difference in the small number of
deaths between the percutaneous coronary intervention
(PCI) and the optimal MT groups, but when combined
with the 2 small previous studies, the role of routine
revascularization for asymptomatic SIHD patients with
ischemia comes into question.
In this issue of the Journal, Aldweib et al. (7) report a
single-site observational study that adds to the available
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ischemia. The authors compared survival of asymptomatic
patients with previous revascularization and documented
ischemia at later follow-up, who were then selected by their
treating physicians to undergo repeat revascularization or
continue on MT. Ischemia was documented with single-
photon emission computed tomography 5 years after the
initial revascularization. The authors selected asymptomatic
post-revascularization patients because appropriate-use cri-
teria have deemed functional testing to be appropriate for
asymptomatic patients 5 years after coronary artery bypass
graft (CABG) but uncertain5 years after CABG or at any
time for asymptomatic patients with previous PCI (8). The
authors identified 6,750 consecutive patients with previous
revascularization (CABG or PCI) who underwent stress
single-photon emission computed tomography between
2005 and 2007, then excluded symptomatic patients and/or
those without ischemia, leaving 769 patients with silent
ischemia. Patients were followed up over 5.7 years for
all-cause death. Patients were separated into those selected
for MT (n  654) or revascularization (n  115). Those
who underwent repeat revascularization realized no survival
benefit over those who received MT either in propensity-
matched groups or unadjusted and adjusted analyses. None
of the imaging variables, including severity of ischemia, was
associated with all-cause death.
The study by Aldweib et al. (7) is discordant with
ACIP and SWISSI II results (4,5) and supports the
position that (repeat) revascularization of asymptomatic
post-revascularization patients does not improve survival.
The study is subject to selection bias because unlike a
randomized trial, assignment to treatment was not random
but was due to unmeasured variables, including physician
and patient preferences. To mitigate bias, the authors
developed a propensity score to adjust for nonrandomiza-
tion, modeled the decision to refer to revascularization, and
used a Cox proportional hazards model to assess the
association of revascularization with mortality, with and
without adjustment for the propensity score.
Observational studies, however, cannot account for un-
measured confounding variables that may affect the out-
come of interest. Patients selected for conservative therapy
are often sicker than patients selected for invasive therapy,
and observational studies most often report better outcomes
with revascularization. (In contrast, randomized trials in
SIHD have not shown superiority for a strategy of routine
revascularization [9–11].) A remarkable finding in the
current report (7) is that, despite selection bias, unadjusted
and adjusted outcomes were not superior for those selected
for revascularization. Another important limitation is that
only patients who survived an average of 5 years after their
initial revascularization were included, thereby introducing
survival bias. Although the findings are intriguing, ulti-
mately the only way to know whether a treatment strategy is
effective is by performing a randomized controlled trial.
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vational study from Cedars-Sinai that found patients with
myocardial ischemia 10% who underwent revasculariza-
ion had lower cardiac mortality than patients who were
reated medically (12). That analysis, however, excluded
atients with previous revascularization and included symp-
omatic patients. Importantly, the nuclear substudy of
OURAGE patients with at least moderate ischemia at
aseline, with or without angina, found no reduction in
eath or myocardial infarction from PCI (13).
What is the take-home point for the clinician? Most
vidence suggests that more severe ischemia is associated
ith worse outcomes, probably because severe stenoses that
ause ischemia are a marker of greater atherosclerotic
urden. Whether revascularization for ischemia-producing
tenoses improves survival beyond the benefit of aggressive
T to stabilize vulnerable plaques is unknown. The current
eport (7) calls into question the association of ischemia and
utcome in patients with remote revascularization. The
trength of the current data may not be sufficient to reclassify
he appropriateness score for post-revascularization stress test-
ng in asymptomatic patients (5 years after CABG; no
ecommendation after PCI), but it calls into question its
tility. The ongoing National Heart, Lung, and Blood
nstitute–funded ISCHEMIA (International Study of
omparative Health Effectiveness With Medical and Invasive
pproaches; NCT01471522) randomized controlled trial will
provide further evidence. The trial is enrolling SIHD
patients with at least moderate ischemia who are either
asymptomatic or symptomatic, with or without previous
revascularization, and testing whether a routine invasive
strategy with revascularization improves prognosis. As trial
leaders, we believe there is equipoise regarding the optimal
management strategy for patients with ischemia who do not
require revascularization for symptoms and encourage support
for answering this important clinical question. In the mean-
time, it is reasonable to follow existing guidelines for SIHD
patients with high-risk ischemia and participate in shared
decision making with such patients (14).
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